Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 March;47(1) > The Quarterly Journal of Nuclear Medicine 2003 March;47(1):58-62

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2003 March;47(1):58-62

THERAPY RESPONSE IN NUCLEAR MEDICINE
Guest Editor: Bombardieri E. 

Tetrofosmin as predictors of tumour response

Fuster D. 1, Viñolas N. 2, Mallafré C. 3, Pavia J. 1, Martín F. 1, Pons F. 1

1 Nuclear Med­i­cine Depart­ment
2 Oncology Depart­ment
3 Pathology Depart­ment Hos­pital ­Clínic, Bar­ce­lona, ­Spain

Non-inva­sive ­imaging ­methods in the eval­u­a­tion of chem­o­therapy ­response in malig­nant ­tumours are cur­rently ­being ­explored. Stan­dard ­Nuclear Med­i­cine pro­ce­dures ­seem to ­offer the cli­ni­cian a prom­ising ­tool in the man­age­ment of ­those onco­logic ­patients, who ­might ben­efit ­from chem­o­therapy. ­Early ­studies ­focused on the rela­tion­ship ­between radio­nu­clides ­used in ­tumour diag­nosis and fac­tors asso­ciated ­with mul­ti­drug resis­tance (MDR). The ­tumour expres­sion of P-gly­co­pro­tein (Pgp) and mul­ti­drug resis­tance-­related pro­tein-1 expres­sion (MRP) ­have ­been sug­gested as impor­tant fac­tors in the ­failure of chem­o­therapy. ­Most ­studies ­found an asso­ci­a­tion ­between Pgp ­levels and 99mTc-ses­ta­mibi (99mTc-­MIBI) or 99mTc-Tet­ro­fosmin ­uptake (99mTc-TF). Cur­rently inves­ti­ga­tions in ­nuclear med­i­cine ­oncology are ­focusing on the poten­tial ­role of radio­nu­clide ­imaging in the assess­ment of chem­o­therapy. ­Recent ­papers dis­cuss the use­ful­ness of radio­nu­clides as 99mTc-­MIBI and 99mTc-TF as non-inva­sive pro­ce­dures to pre­dict and to mon­itor ­therapy ­response in ­patients ­affected by malig­nant ­tumours treat­able ­using chem­o­therapy. ­This ­chapter ­will ­review the ­latest devel­op­ment in 99mTc-TF, ­giving an over­view of ­recent inves­ti­ga­tions car­ried out ­using ­this radio­tracer in ­therapy ­oncology, ­with ­emphasis on its poten­tial ­role as pre­dictor of ­tumour ­response.

language: English


FULL TEXT  REPRINTS

top of page